COGENT BIOSCIENCES ANNOUNCES POSITIVE DATA FROM ONGOING PHASE 2 APEX TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) 56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg...
COGENT BIOSCIENCES ANNOUNCES POSITIVE INITIAL DATA FROM PHASE 2 SUMMIT TRIAL EVALUATING BEZUCLASTINIB IN PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS (NONADVSM) Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of...
COGENT BIOSCIENCES PRESENTS NEW PRECLINICAL DATA HIGHLIGHTING POTENTIAL BEST-IN-CLASS POTENCY AND SELECTIVITY OF ERBB2 AND PI3KΑ INHIBITOR PROGRAMS AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior...
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program – Overall response rate of 42% and median progression-free survival of 11.1 months in heavily...
Recent Comments